MADISON, Wis.--(BUSINESS WIRE)--Stealth Therapeutics Inc. announced today that its Invisiport has been implanted in a patient for the first time.
Rachel, an 18 year-old from northern California, recently received an Invisiport to help with the treatment of her dysmotility syndrome. Dysmotility syndrome affects a person’s ability to digest certain foods requiring intravenous nutrition. Rachel is able to access her Invisiport two times per week on her own to provide the necessary intravenous nutrition required to treat her condition.
